Seegene to set up joint venture with Werfen in Spain

Seegene, a Korean diagnostics firm, announced that it has finalized a technology-sharing contract with Werfen, Spain’s leading diagnostics company, to establish a new joint venture (JV) in Spain.

The new JV is expected to be launched in the first half of next year, following the completion of necessary government approvals. The partnership is Seegene’s second major milestone in its technology-sharing initiative, following the establishment of Hylabs-Seegene in Israel last year.

Seegene's technology-sharing initiative aims to provide its cutting-edge diagnostic and data analysis technologies, such as syndromic quantitative polymerase chain reaction (PCR) and the Seegene digitalized development system (SGDDS), to leading companies worldwide.

By sharing its technological expertise, Seegene expects that local experts and scientists will be able to develop tailored diagnostic products that address diseases in humans, animals, and plants.

Under the Werfen-Seegene partnership, Seegene will share its proprietary technology, while Werfen will leverage its extensive local market infrastructure and networks to develop products specifically tailored to Spain’s needs.

Notably, the JV plans to prioritize the development of diagnostic products for drug resistance testing, blood tests, organ transplant monitoring, and sexually transmitted infections (STIs), and play a leading role in obtaining CE-IVDR approval for in vitro diagnostic medical devices developed by the JV in Europe.

“We are thrilled to establish the Werfen-Seegene JV, combining our expertise to meet the growing demand for products that address new infectious diseases and viral mutations in Spain and Portugal,” Werfen CEO Carlos Pascual said. “The partnership will enable us to respond swiftly to any future outbreaks.”

Seegene CEO Chun Jong-yoon also said, “We have high expectations for the Werfen-Seegene JV, which will combine Werfen’s extensive business experience with Seegene’s world-leading capabilities in Syndromic product development and production.”

Seegene remains committed to sharing its technology with global partners to build a world free from disease, Chun added.